CB2 Insights Completes Purchase of Colorado-based Relaxed Clarity with Surpassed Initial Targets and Provides Additional Corporate Updates
cannabis investing CB2 Insights Announces Delay in Filing Under CSA Instrument Governing Relief Under COVID-19 Duress
cannabis investing CB2 Insights Launches Industry’s First Medical Cannabis Insights Dashboard for All Medical Cannabis Stakeholders
cannabis investing CB2 Insights Appoints Healthcare Industry Expert and Former IQVIA Executive Tom Brogan to its Board of Directors
cannabis investing CB2 Insights Announces Industry’s First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.)
cannabis investing CB2 Insights Announces Collaboration with FCM Global to Support Medical Cannabis R&D in Colombia
cannabis investing CB2 Insights to Participate at Piper Jaffray’s 31st Annual Healthcare Conference
cannabis investing CB2 Insights Announces Record Revenue of $4.2 million for the Third Quarter 2019, Sequential Growth of 29 Percent
cannabis investing CB2 Insights Announces Record Preliminary Unaudited Q3 2019 Revenue of $4.2 Million and Details for Earnings Call
Group Eleven Drills 6.2m of 312 g/t Ag and 0.95% Cu, incl. 2.8m of 549 g/t Ag and 1.77% Cu in a 90m Step-Out, Further Supporting Deeper Cu-Ag Target at Ballywire
